Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 47: 703-711, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piironen, T.
Right arrow Articles by Pettersson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piironen, T.
Right arrow Articles by Pettersson, K.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:703-711.)
© 2001 American Association for Clinical Chemistry, Inc.


Articles

Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing

Timo Piironen1, Martti Nurmi4, Kerttu Irjala5, Olli Heinonen3, Hans Lilja6, Timo Lövgren2 and Kim Pettersson2,a

1 The Finsen Laboratory af.sn. 8621, Strandboulevarden 49, 2100 Copenhagen, Denmark.

2 Department of Biotechnology and
3 Paavo Nurmi Center, University of Turku, 20520 Turku, Finland.

4 Department of Surgery, Turku University Central Hospital, 20520 Turku, Finland.

5 Department of Clinical Chemistry, Turku University Central Hospital, 20520 Turku, Finland.

6 Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital, 20502 Malmö, Sweden.
a Author for correspondence. Fax 358-2-3338050; e-mail kim.pettersson{at}utu.fi.

Background: The purpose of this study was to validate the use of whole-blood samples in the determination of circulating forms of prostate-specific antigen (PSA).

Methods: Blood samples of hospitalized prostate cancer and benign prostatic hyperplasia patients were collected and processed to generate whole-blood and serum samples. Three different rapid two-site immunoassays were developed to measure the concentrations of total PSA (PSA-T), free PSA (PSA-F), and PSA-{alpha}1-antichymotrypsin complex (PSA-ACT) to detect in vitro changes in whole-blood samples immediately after venipuncture. The possible influence of muscle movement on the release of PSA from prostate gland was studied in healthy men by measuring the rapid in vitro whole-blood kinetics of PSA forms before and after 15 min of physical exercise on a stationary bicycle.

Results: Rapid PSA-T, PSA-F, and PSA-ACT assays were designed using a 10-min sample incubation. No significant changes were detected in the concentrations of PSA-T, PSA-F, and PSA-ACT from the earliest time point of 12–16 min compared with measurements performed up to 4 h after venipuncture. Physical exercise did not influence the concentrations of the circulating forms of PSA. Hematocrit-corrected whole-blood values of PSA-T and PSA-F forms were comparable to the respective serum values. Calculation of the percentage of PSA-F (PSA F/T ratio x 100) was similar irrespective of the sample format used, i.e., whole blood or serum.

Conclusions: We found that immunodetectable PSA forms are likely at steady state immediately after venipuncture, thus enabling the use of anticoagulated whole-blood samples in near-patient settings for point-of-care testing, whereas determinations of PSA (e.g., PSA-T, PSA-F, or PSA-ACT) performed within the time frame of the office visit would provide results equivalent to conventional analyses performed in serum.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
Q.-P. Qin, M. Christiansen, and K. Pettersson
Point-of-Care Time-resolved Immunofluorometric Assay for Human Pregnancy-associated Plasma Protein A: Use in First-Trimester Screening for Down Syndrome
Clin. Chem., March 1, 2002; 48(3): 473 - 483.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. A. Stamey
Preoperative Serum Prostate-specific Antigen (PSA) Below 10 {micro}g/L Predicts Neither the Presence of Prostate Cancer Nor the Rate of Postoperative PSA Failure
Clin. Chem., April 1, 2001; 47(4): 631 - 634.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.